Major bleeding increases the risk of subsequent cardiovascular events in patients with atrial fibrillation: Insights from the SAKURA AF registry and RAFFINE registry

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, and its rate of incidence continues to increase ^{1, 2}. Overall, AF increases the risk of thromboembolic stroke; therefore, patients with AF often require treatment with an oral anticoagulant (OAC) such as vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) ². Recent guidelines have recommended DOACs over VKAs ². In a recent meta-analysis, DOACs were associated with significant reductions of 19% for the risk of stroke/systemic embolism and 51% for hemorrhagic stroke, compared with VKAs ³. However, bleeding events remain a major concern even in patients using DOACs because major bleeding is not uncommon and is associated with adverse cardiovascular events ^4–6. A sub-analysis of the ARISTOTLE trial demonstrated that major bleeding in patients taking OACs increased the risk of mortality, stroke, or myocardial infarction (MI) within 30 days after major bleeding events ⁷. However, this sub-analysis demonstrated the relationship between bleeding and adverse events only in the short term, and there are few reports regarding whether bleeding is involved in long-term cardiovascular events. The aim of the present study was to evaluate long-term clinical outcomes after a major bleeding event in patients with AF who were taking OACs, using data from two Japanese multicenter, prospective registries.

Methods

Results

Patients and baseline characteristics

After combining the RAFFINE and SAKURA registry data, we enrolled 7,167 patients with AF. Excluded were those without follow-up data (N = 54) and those not taking OAC (N = 480). A final total of 6,633 patients were assessed in the present study (Figure 1). The median follow-up period was 39.7 (IQR, 33.1–48.1) months. Mean patient age was 72 years, 71% were male, 36% had paroxysmal AF, mean CHADS₂ score was 1.9, and 20% were taking antiplatelet drugs in addition to OACs.

• Download figure
• Open in new tab

Figure 1.

Flow chart of patient selection

After the RAFFINE (N = 3,901) and SAKURA (N = 3,266) registry data were combined, 7,167 patients with AF were enrolled. After excluding patients without follow-up data (N = 54) and those who were not taking OAC (N = 480), a final total of 6,633 patients were assessed in the present study. During follow-up, 298 (4.5%) patients had a major bleeding event.

AF; atrial fibrillation, OAC; oral anticoagulant.

Among the 6,633 patients, 298 (4.5%) had a major bleeding event during follow-up, with incidence of 1.38 per 100 patient-years. Table 1 lists the patient characteristics at baseline, stratified by occurrence of a major bleeding event during the follow-up period. Patients with an incident of major bleeding were significantly older, more likely to have ischemic heart disease and previous stroke, and were more often taking VKA and antiplatelet drugs than those without an incident of major bleeding. Baseline CHADS₂, CHA₂DS₂-VASc, and HAS-BLED score were significantly higher and hemoglobin level was significantly lower in patients with major bleeding.

View this table:

• View inline
• View popup

Table 1.

Baseline clinical characteristics

Clinical outcomes

Table 3 shows the incidences of primary and secondary outcomes. The rate of incidence for each clinical event was significantly higher in patients with major bleeding than in those without. MACCE occurred in 72 patients after major bleeding and in 665 patients without major bleeding (18.33 and 3.22 per 100 patient-years, respectively). The median duration of MACCE after major bleeding was 41 (IQR, 3–300) days. All-cause death occurred in 65 patients after major bleeding and in 464 patients without major bleeding (16.32 and 2.21 per 100 patient-years, respectively). Cardiovascular death occurred in 24 patients after major bleeding and in 192 patients without major bleeding (6.02 and 0.91 per 100 patient-years, respectively). Median duration until death and until cardiovascular death after major bleeding were 43 and 13 days, respectively. Kaplan–Meier analysis showed that occurrences of MACCE and all-cause death were significantly and clearly higher in patients after major bleeding compared with those without major bleeding (both log-rank p <0.0001; Figures 2, 3).

View this table:

• View inline
• View popup
• Download powerpoint

Table 3.

Clinical events and risk after major bleeding events

• Download figure
• Open in new tab

Figure 2.

Rates of major adverse cardiac and cerebrovascular events (MACCE) in patients with and without major bleeding

Development of MACCE was significantly and clearly higher after major bleeding than without major bleeding (log-rank p <0.0001).

MACCE; major adverse cardiac and cerebrovascular events.

• Download figure
• Open in new tab

Figure 3.

All-cause mortality in patients with and without major bleeding

Development of MACCE was significantly and clearly higher after major bleeding than without major bleeding (log-rank p <0.0001)

Multivariate Cox hazard regression analysis showed that risk of MACCE was significantly higher in patients after major bleeding compared with those without major bleeding (HR, 4.64; 95% CI, 3.62–5.94; p <0.0001; Table 3). Multivariate Cox hazard analysis showed that major bleeding was also associated with the incidence of all-cause death and of cardiovascular death (HR, 5.84; 95% CI, 4.48–7.63; p <0.0001 and HR, 4.97; 95% CI, 3.22–7.67; p <0.0001, respectively; Table 3).

Discussion

In the present study, we investigated the association between major bleeding and long-term cardiovascular events in patients with AF who were taking OAC. The major findings were as follows: (1) during follow-up, 4.5% of patients (1.38 per 100 patient-years) experienced major bleeding events; (2) older age, VKA use, and antiplatelet drug use were independently associated with incidence of major bleeding events; (3) 24% of patients with major bleeding had MACCE during long-term follow-up (18.33 per 100 patient-years); (4) patients who experienced major bleeding had significantly higher risks of MACCE, all-cause death, and cardiovascular death, and these adverse events occurred relatively early after major bleeding occurred.

As major bleeding events were found to lead to worse clinical outcomes, it is important to pay careful attention to the risk of major bleeding in patients with AF who are taking OACs. A previous report from the ARISTOTLE trial showed that older age, prior bleed, prior stroke, diabetes, lower creatine clearance, decreased hematocrit level, and use of aspirin and nonsteroidal inflammatory drugs were independent predictors of major bleeding among patients with AF ¹². In addition, recent studies have shown that bleeding risk is higher with VKAs than with DOACs ^{13, 14}. Switching to a DOAC should be considered for patients receiving a VKA, particularly in those with high bleeding risk ¹³. The present study found that as well as VKAs, antiplatelet drug use was related to major bleeding events. AF patients with coronary artery disease (CAD) usually take antiplatelet drugs, and 20% of the present patients used these drugs. The AFIRE trial demonstrated that DOAC monotherapy was noninferior to combination therapy with DOAC plus a single antiplatelet agent in terms of efficacy, and was superior in terms of safety in patients with AF and stable CAD ¹⁵. Therefore, for patients using both OAC and antiplatelet drugs, it is important to evaluate the necessity for continuation of antiplatelet drugs.

Previous reports have shown that major bleeding increased the risk of cardiovascular events in AF patients in the first 30 days after a bleeding event ^{7, 12}. Recently, Meyer et al evaluated the long-term risk of adverse clinical outcomes in AF patients with a newly documented bleeding episode ¹⁶. They reported median time to an adverse outcome event of 142 days after a major bleed. In contrast, the median time until development of MACCE after a major bleed in the present study was only 41 days. Kaikita et al. investigated the association between bleeding and cardiovascular events in AF patients with stable CAD. Their time-adjusted multivariate analysis showed a temporal association between major bleeding and subsequent MACCE, with a particularly high risk of developing MACCE within 1 month after a major bleed ¹⁷. Even in studies with long-term observation, post-bleeding events occurred relatively early; therefore, careful observation of patients with AF is required during that period.

There are several possible explanations for the increased risk of MACCE after major bleeding. First, bleeding itself is a direct cause of cardiovascular events. Bleeding can be fatal and anemia due to bleeding might lower the threshold for ischemia or heart failure. Acute anemia results in decreased blood supply and sudden hypoxia to the heart. In addition, it exacerbates the preexisting compromised coronary blood supply in patients with CAD, and there is a disproportionate oxygen supply and demand ratio to the heart ^{18, 19}. Second, OACs are often discontinued in an effort to control major bleeding ²⁰. A previous study has reported that discontinuation of OAC after bleeding episodes was associated with a higher risk of adverse outcomes ¹⁶. Thus, early resumption of OAC is preferable after hemostasis is achieved and the clinical condition is stabilized, especially in patients with high thrombotic risk. Conversely, restarting OAC after a bleeding event has also been associated with increased risk of recurrent bleeds ^{21, 22}. Determining the optimal timing for restarting anticoagulation has the dual therapeutic aims of preventing thrombotic events while minimizing rebleeding, and should be discussed by the medical team. In patients with recurrent severe bleeding and in those who are not able to restart anticoagulation, nonpharmacological therapies such as left atrial appendage closure or occlusion should be considered. Third, the present patients with major bleeding had higher prevalences of ischemic heart disease and prior stroke, and higher CHADS₂ and HAS-BLED scores than those without major bleeding. In other words, patients at high risk of bleeding not only have an increased risk of bleeding but also an elevated risk of cardiovascular events. Therefore, we should be aware of bleeding as well as cardiovascular events in these patients.

This study had several limitations. First, as a prospective observational study, unknown confounding factors or selection bias might have affected the outcomes, regardless of the analytical adjustments. Second, it was unknown whether patients who had experienced major bleeding events discontinued OACs, and when they restarted anticoagulation therapy. It is also possible that some patients might have changed the type of OAC taken or lowered their dosage to reduce bleeding risks during the course of the study.

Conclusions

In the present analysis of data from two large-scale prospective registries, major bleeding was associated with long-term adverse cardiovascular events among AF patients taking OACs. Therefore, to improve clinical outcomes in patients with AF, it is important to reduce bleeding risks. When a major bleeding event occurs, patients should be monitored carefully for cardiovascular events, especially in the early phase after bleeding.

Funding

This work was supported by scholarship funds received from the following (in alphabetical order): Abbott Japan, Astellas Pharma, AstraZeneca, Bayer Healthcare, Boehringer-Ingelheim, Boston Scientific Japan, Bristol-Meyers Squibb, Crosswill Medical, Daiichi-Sankyo, Eisai, Fukuda Denshi, FUJIFILM RI Pharma, Japan Lifeline, Kowa Pharmaceutical, Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Medical Hearts, Medtronic Japan, Mochida, MSD, Nippon Shinyaku, Otsuka Pharmaceutical, Pfizer, Philips Respironics, Roche Diagnostics, Sanwa Kagaku Kenkyusho, Sanofi, Shionogi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Nihon Medi-Physics. This study was conducted as investigator-initiated research based on a contract with, and financially supported by, Bayer Yakuhin Ltd.

The funding sources had no roles in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Disclosures

Dr. Daida has accepted remuneration from Daiichi-Sankyo, Kowa, MSD, Novartis Pharma, and Bayer Yakuhin, Sanofi K.K., Taisho Pharmaceutical, Abott Medical, Otsuka, Amgen K.K., Pfizer, Fukuda Denshi, Tsumura, Toa Eiyo; received research grants from Philips Japan, Toho Holdings, Asahi Kasei, Fujifilm holdings; Inter Reha, Glory, BMS, Abott, and Boehringer Ingelheim and received scholarship funds from Daiichi-Sankyo, Bayer Yakuhin, and Eisai.

Dr. Matsumoto has lecture’s fee from Nihon Medi-physics and PDRadio Pharma, and has received scholarship donation from PDRadio Pharma.

Dr. Miyauchi has accepted remuneration from Astellas, MSD, Bayer Yakuhin, Sanofi, Daiichi-Sankyo, Boehringer-Ingelheim, and Bristol-Myers Squibb.

Dr. Minamino serves as a consultant to Fukuda Denshi; has accepted remuneration from Kowa, Mitsubishi Tanabe, Daiichi-Sankyo, Bayer Yakuhin, Boehringer-Ingelheim, AstraZeneca KK, Medtronic Japan, Otsuka, Novartis Pharma, Takeda, MSD, Actelion, and Biotronik Japan; accepted research grants from Boehringer-Ingelheim, Bourbon Corporation, and Astellas Pharma; and received scholarship funds from Medical Hearts, Abbott Medical Japan, Japan Lifeline, Medtronic Japan, Mochida, Roche Diagnostics, Takeda, Crosswill Medical, Daiichi-Sankyo, Boehringer-Ingelheim, Boston Scientific Japan, Kowa, Otsuka, Bristol-Myers Squibb, Fukuda Denshi, and Astellas.

Dr. Okumura has received research funding from Bayer Healthcare and Biosense Webster, Inc., scholarship donation from Boston Scientific Japan, and Endowed Courses from Boston Scientific Japan, Japan life line, Fukuda Denshi, Abbott Japan, BIOTRONIK Japan, Medtronic Japan, and has accepted remuneration from Bayer Healthcare, Daiichi-Sankyo, Bristol-Meyers Squibb, AstraZeneca K.K., Ono Pharmaceutical, and Medtronic Japan.